Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years
- PMID: 35907848
- PMCID: PMC9339183
- DOI: 10.1186/s12885-022-09940-3
Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years
Abstract
Background: The disease burden of non-melanoma skin cancer (NMSC) has become a significant public health threat. We aimed to conduct a comprehensive analysis to mitigate the health hazards of NMSC.
Methods: This study had three objectives. First, we reported the NMSC-related disease burden globally and for different subgroups (sex, socio-demographic index (SDI), etiology, and countries) in 2019. Second, we examined the temporal trend of the disease burden from 1990 to 2019. Finally, we used the Bayesian age-period-cohort (BAPC) model integrated nested Laplacian approximation to predict the disease burden in the coming 25 years. The Norpred age-period-cohort (APC) model and the Autoregressive Integrated Moving Average (ARIMA) model were used for sensitivity analysis.
Results: The disease burden was significantly higher in males than in females in 2019. The results showed significant differences in disease burden in different SDI regions. The better the socio-economic development, the heavier the disease burden of NMSC. The number of new cases and the ASIR of basal cell carcinoma (BCC) were higher than that of squamous cell carcinoma (SCC) in 2019 globally. However, the number of DALYs and the age-standardized DALYs rate were the opposite. There were statistically significant differences among different countries. The age-standardized incidence rate (ASIR) of NMSC increased from 54.08/100,000 (95% uncertainty interval (UI): 46.97, 62.08) in 1990 to 79.10/100,000 (95% UI: 72.29, 86.63) in 2019, with an estimated annual percentage change (EAPC) of 1.78. Other indicators (the number of new cases, the number of deaths, the number of disability-adjusted life years (DALYs), the age-standardized mortality rate (ASMR), and the age-standardized DALYs rate) showed the same trend. Our predictions suggested that the number of new cases, deaths, and DALYs attributable to NMSC would increase by at least 1.5 times from 2020 to 2044.
Conclusions: The disease burden attributable to NMSC will continue to increase or remain stable at high levels. Therefore, relevant policies should be developed to manage NMSC, and measures should be taken to target risk factors and high-risk groups.
Keywords: Burden; Global; Non-melanoma skin cancer; Predict; Trend.
© 2022. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Figures





Similar articles
-
Global burden of non-melanoma skin cancers among older adults: a comprehensive analysis using machine learning approaches.Sci Rep. 2025 May 1;15(1):15266. doi: 10.1038/s41598-025-99605-5. Sci Rep. 2025. PMID: 40312476 Free PMC article.
-
Global, regional and national incidence, mortality and disability-adjusted life-years of skin cancers and trend analysis from 1990 to 2019: An analysis of the Global Burden of Disease Study 2019.Cancer Med. 2021 Jul;10(14):4905-4922. doi: 10.1002/cam4.4046. Epub 2021 Jun 9. Cancer Med. 2021. PMID: 34105887 Free PMC article.
-
Global, regional, and national trends in the burden of melanoma and non-melanoma skin cancer: insights from the global burden of disease study 1990-2021.Sci Rep. 2025 Feb 18;15(1):5996. doi: 10.1038/s41598-025-90485-3. Sci Rep. 2025. PMID: 39966563 Free PMC article.
-
The epidemiology of pregnancy loss: global burden, variable risk factors, and predictions.Hum Reprod. 2024 Apr 3;39(4):834-848. doi: 10.1093/humrep/deae008. Hum Reprod. 2024. PMID: 38308812 Review.
-
Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019.Lancet Respir Med. 2021 Sep;9(9):1030-1049. doi: 10.1016/S2213-2600(21)00164-8. Epub 2021 Aug 16. Lancet Respir Med. 2021. PMID: 34411511 Free PMC article.
Cited by
-
Pancreatic Cancer and its Attributable Risk Factors in East Asia, Now and Future.Oncologist. 2023 Nov 2;28(11):e995-e1004. doi: 10.1093/oncolo/oyad147. Oncologist. 2023. PMID: 37265056 Free PMC article.
-
Worldwide trends and future projections of fungal skin disease burden: a comprehensive analysis from the Global Burden of Diseases study 2021.Front Public Health. 2025 Jun 4;13:1580221. doi: 10.3389/fpubh.2025.1580221. eCollection 2025. Front Public Health. 2025. PMID: 40535451 Free PMC article.
-
Innovative Topical Patches for Non-Melanoma Skin Cancer: Current Challenges and Key Formulation Considerations.Pharmaceutics. 2023 Nov 3;15(11):2577. doi: 10.3390/pharmaceutics15112577. Pharmaceutics. 2023. PMID: 38004557 Free PMC article. Review.
-
Freedom from Recurrence across Age in Non-Melanoma Skin Cancer Treated with Image-Guided Superficial Radiation Therapy.Geriatrics (Basel). 2024 Sep 5;9(5):114. doi: 10.3390/geriatrics9050114. Geriatrics (Basel). 2024. PMID: 39311239 Free PMC article.
-
Use of Social Media by the Public Regarding Skin Health: Effects on Dermatological Awareness and Preventive Behaviours.Acta Derm Venereol. 2023 Dec 13;103:adv15341. doi: 10.2340/actadv.v103.15341. Acta Derm Venereol. 2023. PMID: 38088787 Free PMC article. No abstract available.
References
-
- Cheraghi N, Cognetta A, Goldberg D. Radiation therapy in dermatology: non-melanoma skin Cancer. J Drugs Dermatol. 2017;16(5):464–469. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials